glp 1 agonist oral FDA just approved orforglipron (Foundayo), Eli Lilly's GLP-1 receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest glp-1_analogs [TUSOM | Pharmwiki]
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
![glp 1 agonist oral FDA just approved orforglipron (Foundayo), Eli Lilly's GLP-1 receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
![glp 1 agonist oral FDA just approved orforglipron (Foundayo), Eli Lilly's GLP-1 receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest glp-1_analogs [TUSOM | Pharmwiki]](https://cdn.prod.website-files.com/6518fc1601bb06d3facf5039/69b60795933343059286cc12_aec07872-39ca-4671-9036-3ae493ef983f_2000x1260.webp)
![glp 1 agonist oral FDA just approved orforglipron (Foundayo), Eli Lilly's GLP-1 receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest glp-1_analogs [TUSOM | Pharmwiki]](https://www.dcatvci.org/wp-content/uploads/2025/06/iStock-1353657651.jpg)






















